APA (7th ed.) Citation

A, U., Y, D., J, D., H, W., H, Q., A, N., . . . A, D. J. (2026). Safety and immunologic impact of neoadjuvant/adjuvant GVAX, cyclophosphamide, pembrolizumab, and anti-CSF1R agent IMC-CS4 in pancreatic adenocarcinoma. Frontiers in immunology, 17, 1715761. https://doi.org/10.3389/fimmu.2026.1715761

Chicago Style (17th ed.) Citation

A, Urman, et al. "Safety and Immunologic Impact of Neoadjuvant/adjuvant GVAX, Cyclophosphamide, Pembrolizumab, and Anti-CSF1R Agent IMC-CS4 in Pancreatic Adenocarcinoma." Frontiers in Immunology 17 (2026): 1715761. https://doi.org/10.3389/fimmu.2026.1715761.

MLA (9th ed.) Citation

A, Urman, et al. "Safety and Immunologic Impact of Neoadjuvant/adjuvant GVAX, Cyclophosphamide, Pembrolizumab, and Anti-CSF1R Agent IMC-CS4 in Pancreatic Adenocarcinoma." Frontiers in Immunology, vol. 17, 2026, p. 1715761, https://doi.org/10.3389/fimmu.2026.1715761.